These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 16625842)
1. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. Schmid HA; Silva AP J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842 [TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843 [TBL] [Abstract][Full Text] [Related]
3. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Silva AP; Schoeffter P; Weckbecker G; Bruns C; Schmid HA Eur J Endocrinol; 2005 Sep; 153(3):R7-R10. PubMed ID: 16131595 [TBL] [Abstract][Full Text] [Related]
4. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295 [TBL] [Abstract][Full Text] [Related]
6. Somatostatin and its receptor family. Patel YC Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861 [TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo. Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056 [TBL] [Abstract][Full Text] [Related]
8. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Weckbecker G; Briner U; Lewis I; Bruns C Endocrinology; 2002 Oct; 143(10):4123-30. PubMed ID: 12239124 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor subtypes 2 and 5 mediate inhibition of egg yolk-induced gall bladder emptying in mice. Kaczmarek P; Singh V; Cashen DE; Yang L; Berk S; Pasternak A; Xiong Y; Shen DM; Hutchins SM; Chapman K; Wiedenmann B; Schaeffer JM; Strowski MZ Neurogastroenterol Motil; 2010 Feb; 22(2):204-9, e66. PubMed ID: 19754922 [TBL] [Abstract][Full Text] [Related]
10. The release of growth hormone (GH): relation to the thyrotropic- and corticotropic axis in the chicken. Kühn ER; Geelissen SM; Van der Geyten S; Darras VM Domest Anim Endocrinol; 2005 Jul; 29(1):43-51. PubMed ID: 15927766 [TBL] [Abstract][Full Text] [Related]
11. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628 [TBL] [Abstract][Full Text] [Related]
12. Effects of somatostatin analogs on glucose homeostasis in rats. Schmid HA; Brueggen J J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782 [TBL] [Abstract][Full Text] [Related]
13. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. Osapay G; Prokai L; Kim HS; Medzihradszky KF; Coy DH; Liapakis G; Reisine T; Melacini G; Zhu Q; Wang SH; Mattern RH; Goodman M J Med Chem; 1997 Jul; 40(14):2241-51. PubMed ID: 9216843 [TBL] [Abstract][Full Text] [Related]
14. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841 [TBL] [Abstract][Full Text] [Related]